<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Alpana and Murari Chaudhuri on Medium]]></title>
        <description><![CDATA[Stories by Alpana and Murari Chaudhuri on Medium]]></description>
        <link>https://medium.com/@achaudhuri47?source=rss-7c0660a6f984------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/0*LAPgnR30TxqvawbN.</url>
            <title>Stories by Alpana and Murari Chaudhuri on Medium</title>
            <link>https://medium.com/@achaudhuri47?source=rss-7c0660a6f984------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Thu, 19 Nov 2026 08:08:13 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@achaudhuri47/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Why are gram-negative bacteria resistant to antibiotics?]]></title>
            <link>https://medium.com/the-biochemists/why-are-gram-negative-bacteria-resistant-to-antibiotics-c732fe9afd06?source=rss-7c0660a6f984------2</link>
            <guid isPermaLink="false">https://medium.com/p/c732fe9afd06</guid>
            <category><![CDATA[health]]></category>
            <category><![CDATA[disease]]></category>
            <category><![CDATA[biotechnology]]></category>
            <category><![CDATA[bacteria]]></category>
            <category><![CDATA[biology]]></category>
            <dc:creator><![CDATA[Alpana and Murari Chaudhuri]]></dc:creator>
            <pubDate>Sun, 28 Oct 2018 02:08:33 GMT</pubDate>
            <atom:updated>2018-10-28T02:08:33.545Z</atom:updated>
            <content:encoded><![CDATA[<h3>Overview</h3><p>Bacteria can be divided into two groups on the basis of a process known as crystal violet staining, or Gram staining- these groups are known as gram-positive and gram-negative.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/800/1*WkUA4NBG8stuMElHAZOp3g.png" /><figcaption>Membrane structure of gram-negative and gram-positive bacteria.</figcaption></figure><p>Gram-positive bacteria have a thicker layer of peptidoglycan that makes up the cell wall and thus stain purple in a Gram stain test. Gram-negative bacteria have a cell wall composed of a thin layer of peptidoglycan surrounded by an outer membrane. This outer membrane of gram-negative bacteria contains a unique component, lipopolysaccharide, in addition to proteins and phospholipids.</p><p>The outer membrane of gram-negative bacteria is often hidden by a slime layer, which in turn hides the antigens of the cell. The unique structure of the outer membrane of gram-negative bacteria prevents certain drugs and antibiotics from entering into the cell, which means these bacteria have increased resistance to drugs and are more dangerous as disease-causing organisms.</p><p>Gram-negative bacteria cause many types of well-known infections. For instance, gram-negative bacteria are responsible for cholera and the bubonic plague. They can also cause respiratory infections, such as certain types of pneumonia. Gonococci bacteria, which cause venereal diseases, and meningococci, which cause bacterial meningitis are also gram-negative.</p><p>Antibiotics like vancomycin and other b-lactam antibiotics target peptidoglycan, a substance in the bacteria cell wall. However, these antibiotics are ineffective against gram-negative bacteria because the slime layer in the outer membrane hide the antigens and do not allow these antibiotics to penetrate it.</p><p>Gram-negative bacteria have higher levels of transport proteins, which remove toxic substances, such as antibiotics from the cells. Certain gram-negative bacteria can also acquire antibiotic resistance via mutation or acquisition of foreign DNA through gene transfer. One well-known example of this is E. coli, which can cause traveler’s diarrhea and urinary tract infections.</p><p>A few antibiotics, such as broad-spectrum penicillins and fluoroquinolones, are currently used to treat infections caused by gram-negative bacteria. In recent years, infections caused by multidrug-resistant gram-negative bacteria have dramatically increased. One treatment for diseases caused by multidrug-resistant gram negative-bacteria is colistin, an organic polymer, but certain bacteria are even developing a resistance to this.</p><p>Recently, significant progress has been made in understanding the biogenesis, regulation, and function of bacterial outer membranes. This increased knowledge of the outer membrane may be used to develop new antibiotics to treat resistant gram-negative bacteria. One natural compound that scientists are experimenting with is arylomycin, which can go through the bacterial membrane and bind to the antigens in the cell. Some chemical modifications of this compound have been found to be 500 times more effective than unmodified arylomycin. Experiments with modified arylomycin as an antibiotic to treat gram-negative bacteria have shown some promise in mice; the next exciting phases of testing are in large animals and humans.</p><h3>Further Reading</h3><p>Peter A. Smith. Nature (2018) 561,189–194.</p><p>J. van der Hejden, et. al. mbio (2016) 7: e01238–16.</p><p>Beveridge, T. J. J Bacteriol. (1999) 181, 4725–4733.</p><p>J. M. Blair, et. al. Nat Rev Microbiol. (2015) 13, 42–51.</p><h3>Picture Credit</h3><p>Atterx Biotherapeutix. <a href="http://atterx.com/gn-4474/">http://atterx.com/gn-4474/</a>.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=c732fe9afd06" width="1" height="1" alt=""><hr><p><a href="https://medium.com/the-biochemists/why-are-gram-negative-bacteria-resistant-to-antibiotics-c732fe9afd06">Why are gram-negative bacteria resistant to antibiotics?</a> was originally published in <a href="https://medium.com/the-biochemists">The Biochemists</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Hormones and Neurotransmitters: The Differences and Curious Similarities]]></title>
            <link>https://medium.com/the-biochemists/hormones-and-neurotransmitters-the-differences-and-curious-similarities-46c6095b825?source=rss-7c0660a6f984------2</link>
            <guid isPermaLink="false">https://medium.com/p/46c6095b825</guid>
            <category><![CDATA[biology]]></category>
            <category><![CDATA[biochemistry]]></category>
            <category><![CDATA[neuroscience]]></category>
            <category><![CDATA[hormones]]></category>
            <category><![CDATA[medicine]]></category>
            <dc:creator><![CDATA[Alpana and Murari Chaudhuri]]></dc:creator>
            <pubDate>Tue, 26 Jun 2018 06:01:12 GMT</pubDate>
            <atom:updated>2018-06-26T06:04:59.412Z</atom:updated>
            <content:encoded><![CDATA[<h4>Quite curious indeed</h4><figure><img alt="" src="https://cdn-images-1.medium.com/max/500/1*4UydXrilrkLYbESiEOMg8g.jpeg" /><figcaption>A visualization of neurotransmitters. Source: Thermo Fisher Scientific.</figcaption></figure><h4>Overview</h4><p>Neurotransmitters and hormones are two different types of chemicals that carry signals from one part of the body to another. Both chemicals play an important part in the body’s physiology. They control a variety of physical and psychological functions, including our mood, our eating patterns, our ability to learn, and our sleep cycles.</p><h4><strong>The Differences</strong></h4><p>Hormones and neurotransmitters are different chemical messengers, the former produced by the endocrine glands and the latter by the nervous system.</p><p>Hormones are usually secreted from the endocrine system and released into the bloodstream, but they act on distant target cells. Some hormones, like melatonin and cortisol, are actually produced in the brain, released in the blood, and affect other parts of the body.</p><p>On the other hand, neurotransmitters are released from the presynaptic nerve terminal in the brain. They move across the synaptic cleft, a small space between two adjacent neurons, and move to the next neuron (known as a postsynaptic neuron). There they bind to specific receptors, causing changes in the electrical properties of target cells, which can cause various postsynaptic effects. Neurotransmitters work locally and their actions are very fast.</p><p>Both hormones and neurotransmitters influence our thoughts and motivations, as well as our ability to learn and concentrate. However, neurotransmitters’ actions are short-lived while hormones act for longer periods of time. Furthermore, neurotransmitters can affect both voluntary actions (eating, bathing, walking) and involuntary actions (breathing, blinking). Hormones in the endocrine system always work involuntarily.</p><h4><strong>Curious Similarities</strong></h4><p>Research in the last couple of years has demonstrated that some hormones, work like neurotransmitters independently of their classical hormone actions. The most well-studied hormones are progesterone and estrogen, which are known as steroid hormones.</p><p>Steroid hormones are typically synthesized in the endocrine gland and bind to a receptor that then binds to a specific DNA sequence, affecting gene transcription. This process is a lengthy one, which means that steroid hormones work for a prolonged period of time.</p><p>However, Progesterone and estrogen are also synthesized in the neuronal circuit, specifically in the presynaptic terminal. They then bind to the membrane and intracellular receptors followed by neurotransmitter-like action, which is very fast and short-lived. These neurotransmitters-like steroids have multiple receptors. The steroid-receptor specific functions are not yet clearly understood.</p><p>Some well-studied neuroreceptors, like dopamine and serotonin are known to possess hormonal functions. Dopamine is a neurohormone released from the hypothalamus; its main function is to block the release of prolactin, another hormone, from the pituitary gland. As a neurotransmitter released from the central nervous system, it also has many functions including roles in cognition and motor activity.</p><p>Adrenaline and noradrenaline are two molecules that differ by one carbon atom. Adrenaline, which is produced by the adrenal gland, acts as a hormone. On the other hand, noradrenaline acts as a neurotransmitter in the central nervous system.</p><p>This is just a piece of a growing body of research suggesting that many hormones work as neurotransmitters and vice-versa. The next area of research here is to determine the receptor-specificity of these molecules to understand how their function may change depending on the receptor and mode of binding.</p><h4>Further Reading</h4><p>S.F. Owen, et al. (2013). Nature, 500, 458–462.</p><p>B.J. Martin, et al. (2015). Nature, 520, 499–504.</p><p>Lauren M. Rudolph, et al. (2016). The J. of Neuroscience, 36, 11449–11458.</p><p>Balthazart, J. &amp; Ball, G.F. (2006). Trends Neurosci., 29, 241–249.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=46c6095b825" width="1" height="1" alt=""><hr><p><a href="https://medium.com/the-biochemists/hormones-and-neurotransmitters-the-differences-and-curious-similarities-46c6095b825">Hormones and Neurotransmitters: The Differences and Curious Similarities</a> was originally published in <a href="https://medium.com/the-biochemists">The Biochemists</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[The science behind why the flu vaccine isn’t always effective]]></title>
            <link>https://medium.com/the-biochemists/the-science-behind-why-the-flu-vaccine-isnt-always-effective-56acc582a48a?source=rss-7c0660a6f984------2</link>
            <guid isPermaLink="false">https://medium.com/p/56acc582a48a</guid>
            <category><![CDATA[medicine]]></category>
            <category><![CDATA[biochemistry]]></category>
            <category><![CDATA[biology]]></category>
            <category><![CDATA[flu]]></category>
            <category><![CDATA[health]]></category>
            <dc:creator><![CDATA[Alpana and Murari Chaudhuri]]></dc:creator>
            <pubDate>Thu, 10 May 2018 23:18:26 GMT</pubDate>
            <atom:updated>2018-05-10T23:19:20.084Z</atom:updated>
            <content:encoded><![CDATA[<h4>Blame mutation.</h4><h4>Overview</h4><p>The flu is a respiratory illness that affects the nose, throat, and lungs. The typical symptoms of the flu are well-known and include aches, fever, headache, sore throat, cough, exhaustion, congestion, vomiting, and diarrhea. It is caused by the influenza virus, which comes in four types, known as influenza A, B, C, and D.</p><p>Influenza A and B are the most commonly-experienced types among humans; these viruses cause seasonal epidemics most winters in the United States. Influenza C is less common and can cause a mild respiratory illness. Influenza D primarily affects cattle; it’s not known to cause illness in humans.</p><p>Influenza A can be further broken down into subtypes based on proteins that occur on the surface of the virus. These proteins are hemagglutinin (abbreviated H) and neuraminidase (N). Hemagglutinin has 18 subtypes (H1 through H18), while neuraminidase has 11 subtypes (N1 through N11).</p><p>These subtypes present in different strains of the influenza virus. The current subtypes of influenza A found in humans are H1N1 and H3N2. This past year, H3N2 was the dominant strain; however, this is not always the case. For instance, in the spring of 2009, H1N1 caused illness in humans; it was different from the primary influenza A virus circulating at the time and caused the first flu pandemic in more than 40 years.</p><p>The primary method of protection against the flu is the flu vaccine. Flu vaccines introduce a person’s immune system to purified proteins from dead flu viruses; the antibodies made attack the flu viruses when the body comes in contact with them.</p><p>The proteins in the flu vaccine are typically purified from a virus grown in chicken eggs. When World Health Organization scientists choose the strains of influenza virus to make the yearly flu vaccine, they include two strains of influenza A (one variant of H1N1 and one variant of H3N2) and one or two strains of influenza B. These strains are chosen over a period of 6 months because the vaccines take that long to be manufactured and distributed.</p><p>However, the influenza virus mutates and it is very hard to predict which variant of influenza will make people sick during the flu season. For example, at the beginning of 2014–2015 flu season, a mutated version of H3N2 caused the majority of cases of the flu in the United States. The mutated virus was different from the strain of H3N2 that was included in that year’s flu vaccine and as a result the vaccine did not give much protection against the flu.</p><p>The effectiveness of the flu vaccine is a hot topic of recent research. H3N2 viruses continuously acquire mutation in the hemagglutinin glycoprotein, and new studies suggest that the lower effectiveness was due to a substitution at the hemagglutinin glycoprotein of the H3N2 virus. This mutation resulted in the year 2016’s flu vaccine being only 30 percent effective.</p><p>Another study showed that the lack of a glycosylation site, an area in which a carbohydrate attaches to the functional part of a protein, also reduced the effectiveness of the vaccine. Glycosylation is important for virus survival, and this demonstrates that the glycosylation site is necessary for binding of human antibodies. Better understanding of influenza cell-surface HA glycosylation will provide a positive direction for the design of a universal influenza vaccine.</p><h4>Further Reading</h4><p>Zost, S.J., et. al. PNAS. 114 (47), 12578 (2017).</p><p>Yang, H., et. al. Virology. 477, 18 (2015).</p><p>Nicholas, C.W. PLOS Pathogens. 13 (10), 1371 (2017).</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=56acc582a48a" width="1" height="1" alt=""><hr><p><a href="https://medium.com/the-biochemists/the-science-behind-why-the-flu-vaccine-isnt-always-effective-56acc582a48a">The science behind why the flu vaccine isn’t always effective</a> was originally published in <a href="https://medium.com/the-biochemists">The Biochemists</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[The link between gut bacteria and autoimmune disease]]></title>
            <link>https://medium.com/the-biochemists/the-link-between-gut-bacteria-and-autoimmune-disease-2d07ce5330b0?source=rss-7c0660a6f984------2</link>
            <guid isPermaLink="false">https://medium.com/p/2d07ce5330b0</guid>
            <category><![CDATA[bacteria]]></category>
            <category><![CDATA[autoimmune-disease]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[biochemistry]]></category>
            <category><![CDATA[biology]]></category>
            <dc:creator><![CDATA[Alpana and Murari Chaudhuri]]></dc:creator>
            <pubDate>Thu, 22 Mar 2018 16:12:01 GMT</pubDate>
            <atom:updated>2018-03-22T16:13:21.510Z</atom:updated>
            <content:encoded><![CDATA[<p>New research suggests gut bacteria may be linked to autoimmune diseases, such as rheumatoid arthritis and Type 1 diabetes.</p><h4>Overview</h4><p>This is the last entry in our three-part series on gut bacteria and its impact on other parts of the body. We hope you’ve enjoyed this series- let us know what you think in the comments!</p><p>One of the many ways in which microbes residing in the gastrointestinal tract benefit the body is by regulating the body’s immune system.</p><p>A change in the gut microbiota can cause immune dysregulation, and this can lead to autoimmune disorders, a class of disorders in which the body’s immune system attacks healthy cells.</p><p>The gut microbiota does not only regulate the intestinal immune system. It also has a significant role in adaptive immunity, the process by which the body eliminates a pathogen and creates immunological memory to have an enhanced response to that pathogen in the future. The role of gut microbes in shaping both adaptive immunity and innate immunity has been revealed by recent advances in next-generation genome sequencing technology and the development of germ-free mouse models.</p><p>Recent studies have unraveled the role of gut bacteria in both intestinal and extra-intestinal autoimmune disorders.</p><p>Inflammatory Bowel Disease (IBD) is an innate autoimmune disease that affects the gastrointestinal tract. Recent studies have shown that the microbial environment in patients with IBD greatly differs when compared to that of a normal adult. This suggests that intestinal inflammation is a major cause of microbial imbalances in patients with IBD and that a disturbance in the gut microbiota may result in immunological dysregulation, which underlies disorders such as IBD.</p><p>Another important autoimmune disease is Type 1 diabetes. This disease results from T-cell mediated destruction of insulin-producing cells in the pancreas. T-cells, which are the key component of the adaptive immune system can differentiate into four major subtypes, including regulatory T cells (Treg). Treg is a mediator of immune tolerance, and its dysfunction can lead to autoimmune disease. A significant reduction of intestinal Treg was observed in patients with Type 1 diabetes, suggesting the involvement of gut microbiota in the disease.</p><p>Imbalances in gut microbiota can also cause adaptive autoimmune disorders. Recent studies with germ-free mouse models suggest that gut microbes have a role on the severity of rheumatoid arthritis, a disease that causes inflammation of the joints and affects approximately 1% of the world’s population.</p><p>Signals from gut microbes can affect diseases in other areas of the body by regulating systemic immune components. The mechanism by which this happens is not clear, but it may be mediated by the circulation of microbiota-derived soluble factors from the gut to other areas of the body. This can be caused by genetic factors, as well as environmental factors, such as overuse of antibiotics.</p><p>An important next step for researchers in this space is to determine whether changes in gut microbiota are the cause of autoimmune diseases or are a result of the diseases themselves.</p><p>Researchers have also seen that a single new bacterial species within the gut can have a drastic impact on host immunity and pathology. Scientists are currently looking into how microbiota composition varies under different conditions and how this can impact autoimmune disease.</p><h4>Further Reading</h4><p>L. Wen, et al. Nature, 2008, 455(7216):1109–1113.</p><p>SK Mazmanian, JL Round, and DL Kasper. Nature, 2008, 453(7195):620–625.</p><p>WS Garrett, et al. Cell, 2007, 131(1):33–45.</p><p>HJ Wu, et al. Immunity, 2010, 32(6):815–827.</p><p>Hsin-Jung Wu and Eric Wu. Gut Microbes, 2012, 3(1):4–14.</p><p>RH Nanjundappa, Cell, 2017, 171(3):655–667.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=2d07ce5330b0" width="1" height="1" alt=""><hr><p><a href="https://medium.com/the-biochemists/the-link-between-gut-bacteria-and-autoimmune-disease-2d07ce5330b0">The link between gut bacteria and autoimmune disease</a> was originally published in <a href="https://medium.com/the-biochemists">The Biochemists</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[The role of gut microorganisms in the development of colorectal cancer]]></title>
            <link>https://medium.com/the-biochemists/the-role-of-gut-microorganisms-in-the-development-of-colorectal-cancer-626b0272f651?source=rss-7c0660a6f984------2</link>
            <guid isPermaLink="false">https://medium.com/p/626b0272f651</guid>
            <category><![CDATA[biochemistry]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[gut-bacteria]]></category>
            <category><![CDATA[biology]]></category>
            <category><![CDATA[cancer]]></category>
            <dc:creator><![CDATA[Alpana and Murari Chaudhuri]]></dc:creator>
            <pubDate>Thu, 15 Feb 2018 16:24:21 GMT</pubDate>
            <atom:updated>2018-02-15T16:26:27.384Z</atom:updated>
            <content:encoded><![CDATA[<h4>Changes in your gut bacteria may have an impact on your risk for colorectal cancer.</h4><h4>Overview</h4><p>Gastrointestinal microorganisms and their metabolites play a significant role in the maintenance<strong> </strong>of good health. A change in gut microbiota composition, know as dysbiosis, can occur due to a change in diet, exposure to antibiotics, or infection. Dysbiosis can cause gastrointestinal disorders, and recent studies have shown that perturbations in gut microbes may be linked to colorectal cancer.</p><p>The mechanism by which the gut microbial environment can cause colorectal cancer is not well understood. However, new technologies are emerging, which allow for large scale analysis of the genetic and metabolic profile of the gut microbial community. This can help us better understand the composition and function of gut microbiota.</p><p>Dysbiosis (or dysfunction of symbiosis) of gut microbes can promote the development and progression of colorectal cancer via multiple processes. These can include affecting the metabolism of host cells, the biosynthesis of toxic and genotoxic metabolites, and induction of a chronic inflammatory state.</p><p>Another recent study suggests that bacterial density in the large intestine is about 12x greater than that in the small intestine; this correlates with a similar increased risk in cancer for the large intestine, although causality has not been established.</p><p>A few specific microbial species have been found to have an impact on the development of colorectal cancer. Pathogenic E. coli found in the gut can synthesize a toxin known as cytolethal distending toxin (CDT), which has been shown to induce DNA damage. In colorectal cancer patients, E. coli strains have been shown to occur with an increased prevalence of CDT and genotoxin encoding genes, suggesting a link between E. coli and colorectal cancer.</p><p>Other studies indicate that enterotoxigenic bacteroides fragilis (ETBF), a bacterium present in the gut, can lead to colorectal cancer. An ETBF infection can increase T helper 17 and T regulatory cells, causing chronic inflammation and resulting in early tumor development.</p><p>One interesting way to determine the mechanism by which dysbiosis causes colorectal cancer is by investigating drug resistance pathways. Gut microbes and their metabolites can create genotoxic stress; controlling these microbes and their metabolites may be a useful way to reduce drug resistance. Research is underway to determine if this same pathway has an impact on the formation of colorectal cancer.</p><p>Overall, evidence suggests that gut microbes play a role in colorectal cancer development. However, it’s unclear if changes in the gut microbiota are the cause or merely a consequence of colorectal cancer. Further research is needed to determine the underlying mechanism at the molecular level, which will then help us find targeted therapies for colorectal cancer.</p><h4>Further Reading</h4><p>YN Yu, JY Fang. Gastrointestinal Tumors, 2015; 2:26–32.</p><p>J. Gagniere, et al. World Journal of Gastroenterology, 2016; 22:501–518.</p><p>M. Arumugan, et al. Nature, 2011; 473:174–180.</p><p>Iradj Sobhani, et al. Therapeutic Advances in Gastroenterology, 2013; 6(3):215–229.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=626b0272f651" width="1" height="1" alt=""><hr><p><a href="https://medium.com/the-biochemists/the-role-of-gut-microorganisms-in-the-development-of-colorectal-cancer-626b0272f651">The role of gut microorganisms in the development of colorectal cancer</a> was originally published in <a href="https://medium.com/the-biochemists">The Biochemists</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[A curious link between gut bacteria and Parkinson’s disease]]></title>
            <link>https://medium.com/the-biochemists/a-curious-link-between-gut-bacteria-and-parkinsons-disease-125d741bc271?source=rss-7c0660a6f984------2</link>
            <guid isPermaLink="false">https://medium.com/p/125d741bc271</guid>
            <category><![CDATA[biochemistry]]></category>
            <category><![CDATA[microbiology]]></category>
            <category><![CDATA[biology]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[science]]></category>
            <dc:creator><![CDATA[Alpana and Murari Chaudhuri]]></dc:creator>
            <pubDate>Wed, 24 Jan 2018 22:25:52 GMT</pubDate>
            <atom:updated>2018-01-24T22:31:25.845Z</atom:updated>
            <content:encoded><![CDATA[<h4>Recent research suggests that the composition of your intestinal bacteria can cause Parkinson’s disease.</h4><h4>Overview</h4><p>Parkinson’s disease is a degenerative neurological disorder. At present, the pathology of the disease is unknown, but recent research suggests a link between gut bacteria and Parkinson’s.</p><p>Researchers have known for a while that a number of physical changes occur in patients with Parkinson’s disease, especially changes in the digestive system, including constipation, bloating, and indigestion. These typically occur long before loss of motor control, the hallmark of the disease.</p><p>The biological link between gut bacteria and Parkinson’s disease was first discovered by a group of researchers from Caltech. Over the last couple of years, researchers have found significant additional evidence that the gut bacterial environment and enteric nervous system plays a pivotal role in the pathogenesis of the disease.</p><p>Researchers have found that changes in the composition of intestinal bacteria are linked to a number of neurological conditions, including neurodegenerative diseases like Parkinson’s disease. Metabolites produced by intestinal microbes may be either beneficial or pathogenic. An imbalance in the microbial environment of the intestines may lead to the pathogenesis of Parkinson’s disease.</p><p>70% of the neurons outside the central nervous system exist in the intestines; this network of neurons is connected to the brain via a nerve known as the vagus nerve. Scientists believe that this nerve could potentially be the link between changes in the gut and changes in the brain. One piece of supporting evidence is that alpha-synuclein, a sticky protein that clumps in the brain of people with Parkinson’s is also present in the gut of people with Parkinson’s.</p><p>The role of gut bacteria in other bodily functions also suggests a link to Parkinson’s. The gut microbial environment modulates the immune process in the body and the central nervous system. As part of this function, it may induce oxidative toxicity and related inflammation, which is an underlying mechanism for the progress of Parkinson’s. Gut bacteria also plays a role in removing environmental toxins from the body. Previous studies have shown that environmental toxins are linked to an enhanced risk for Parkinson’s disease.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/491/0*EnCu_odv5dB_njJy." /><figcaption>A diagram showing how intestinal inflammation can result in neurodegeneration.</figcaption></figure><p>The gut microbiota has a significant influence on blood-brain barrier (BBB) permeability. Controlled permeability is essential for an integrated BBB structure. The altered microbial environment in the gut of patients upregulates expression of tight junction proteins, such as claudins. Overexpression of these proteins decreases BBB permeability, an effect that is seen in patients with Parkinson’s.</p><p>Furthermore, the BBB gene encodes a glycoprotein (P-gp) with ATPase activity, which controls the transport and exchange of a variety of molecules and nutrients between the circulatory system and the brain parenchyma, the functional tissue in the brain. Patients with Parkinson’s have significantly lower activity of this glycoprotein.</p><p>Researchers are now trying to characterize the gut bacteria from Parkinson’s patients to determine which microbes predispose people to the disorder. If they can identify certain microbes, scientists can find a way to screen for the disease before symptoms appear and damage to the brain and motor occurs.</p><h4>Further Reading and References</h4><p>Yu-Jie Zhang, et al. International Journal of Molecular Science. 2015, 16 (4), 7483–7519.</p><p>Houser, MC and Tansey, MG. Nature Partner Journal. 2017. Doi:10, 1038/s41531–016–0002–0.</p><p>Rudie Kortekaas et al. Annals of Neurology. 2005, 57, 176–179.</p><p>Viorica Braniste et al. Science Translational Medicine. 2014, 6 (263), 263ra 158.</p><p>Agata Mulak and Bruno Bonaz. World Journal of Gastroenterology. 2015, 21(37), 10609–10620.</p><p>Timothy R. Simpson, et al. Cell. 2016, 167(6), 1469–1480.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=125d741bc271" width="1" height="1" alt=""><hr><p><a href="https://medium.com/the-biochemists/a-curious-link-between-gut-bacteria-and-parkinsons-disease-125d741bc271">A curious link between gut bacteria and Parkinson’s disease</a> was originally published in <a href="https://medium.com/the-biochemists">The Biochemists</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[We’re Back!]]></title>
            <link>https://medium.com/the-biochemists/were-back-6428b9edc051?source=rss-7c0660a6f984------2</link>
            <guid isPermaLink="false">https://medium.com/p/6428b9edc051</guid>
            <dc:creator><![CDATA[Alpana and Murari Chaudhuri]]></dc:creator>
            <pubDate>Thu, 18 Jan 2018 08:04:54 GMT</pubDate>
            <atom:updated>2018-01-18T08:04:54.630Z</atom:updated>
            <content:encoded><![CDATA[<p>It’s been quite a while since we last posted. We’ve had a lot going on- we moved from Ohio to California and just settled into our new home. We’ve also renamed our blog and moved it to Medium to give you a better reading experience.</p><p>We’re going to be picking this publication up again and will be posting a lot more going forward- we hope you’re excited to learn a ton more about new research in biology!</p><p>We’re kicking things off with a three part series on the role of gut bacteria in different diseases. Keep an eye out for the next article!</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=6428b9edc051" width="1" height="1" alt=""><hr><p><a href="https://medium.com/the-biochemists/were-back-6428b9edc051">We’re Back!</a> was originally published in <a href="https://medium.com/the-biochemists">The Biochemists</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[9 Things You Should Know About the Dicer Enzyme]]></title>
            <link>https://medium.com/the-biochemists/9-things-you-should-know-about-the-dicer-enzyme-2f022f26c930?source=rss-7c0660a6f984------2</link>
            <guid isPermaLink="false">https://medium.com/p/2f022f26c930</guid>
            <dc:creator><![CDATA[Alpana and Murari Chaudhuri]]></dc:creator>
            <pubDate>Wed, 30 Nov 2016 19:48:13 GMT</pubDate>
            <atom:updated>2017-12-28T22:42:00.186Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="dicer" src="https://cdn-images-1.medium.com/max/200/0*oVIEX6j4zMupcHxN.png" /><figcaption>One molecule of a Dicer protein.</figcaption></figure><h4><strong>Overview</strong></h4><ol><li>Dicer is an enzyme that is encoded in the DICER1 gene in humans. It is an endoribonuclease with helicase activity, which can bind to and remodel nucleic acid. It is particularly important because it cleaves double-stranded RNA (dsRNA) and pre-microRNA (pre-miRNA) into short double stranded RNA fragments called small interfering RNA (siRNA) and micro RNA (miRNA).</li><li>Both siRNA and miRNA have been shown to have a wide variety of cellular functions, including functions related to cancer development and progression. For instance, Dicer-dependent small RNA produced from sequences in the vicinity of double-strand break sites is essential for DNA damage repair. The efficiency of DNA damage repair is greatly reduced in Dicer-deficient cells.</li><li>In addition to the functions of Dicer-produced miRNA and siRNA, Dicer itself has a specific role in age-related macular degeneration, a leading cause of vision loss. In people with macular degeneration, the Dicer level is significantly decreased in the retinal pigment epithelium, the cell layer just outside the retina.</li><li>Dicer and RNA interference are important for regulating chromosome segregation and heterochromatic gene silencing. As a result, Dicer inactivation might lead to an alteration in chromosome segregation and condensation. This can trigger cell death as the body attempts to avoid abnormal cell division and gene expression.</li><li>Dicer plays an important role in the survival of muscle cells. It is required for muscle cell survival during embryogenesis, the development of an embryo. Scientists have also demonstrated that muscle myopathy, muscular dystrophy, and age-related sarcopenia involve Dicer mutation or disrupted miRNA-mediated gene regulation.</li><li>Recent scientific data has demonstrated a relationship between Dicer and miRNA processing in aging and stress. This is an exciting new area for exploration as we continue to learn more about the aging process.</li><li>The deregulation of miRNA is a major indication of human cancer, although the mechanism by which this deregulation occurs is not yet understood. Dicer is essential for mature miRNA production, and it has significant biological and clinical relevance in ovarian cancer, lung cancer, and possibly other cancers.</li><li>Mutation in the Dicer gene leads to an increased risk of tumors in the lungs, ovaries, and thyroid. These mutations lead to the production of abnormally short Dicer proteins that are unable to produce miRNA. Without regulation by miRNA, there will be abnormal gene expression leading to uncontrolled cell growth and tumor formation.</li><li>Once we understand the molecular mechanisms of Dicer and DNA damage-responsive miRNA in cancer development, we will have a starting point for developing novel diagnostic and therapeutic strategies for cancer treatment.</li></ol><h4><strong>Further Reading</strong></h4><p>I.J. MacRae, F. Li, K. Zhou, W.Z. Cande, and J.A. Doudna (2006). Structure of Dicer and Mechanistic Implications for RNAi. Cold Spring Harbor Symposia on Quantum Biology. 71, 73–80.</p><p>Ross C. Wilson and Jennifer A. Doudna (2013). Molecular Mechanisms of RNA interference. Annual Review of Biophysics. 42, 217–239.</p><p>Cameron L. Noland, Enbo Ma, and Jennifer A. Doudna (2011). SiRNA Repositioning for guide strand selection by human Dicer complex. Mol. Cell 43 (1), 110–121.</p><p>Simion Chiosea, Elena Jelezcova, Uma Chandran, Marie Acquafondata, Teresa McHale, Robert W. Sobol, and Rajiv Dhir (2006). AM. J. PATHOL. 169 (5), 1812–1820.</p><p>Sharp, P.A.(1999). RNAi and double-stranded RNA. Genes Dev. 13,139–141.</p><h4><strong>Picture Credit</strong></h4><p>Macrae IJ, Zhou K, Li F, Repic A, Brooks AN, Cande WZ, Adams PD, Doudna JA (Jan 2006). “Structural basis for double-stranded RNA processing by Dicer”. Science. 311 (5758): 195–8.</p><p>“Dicer”. Wikipedia. <a href="https://en.wikipedia.org/wiki/Dicer.">https://en.wikipedia.org/wiki/Dicer.</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=2f022f26c930" width="1" height="1" alt=""><hr><p><a href="https://medium.com/the-biochemists/9-things-you-should-know-about-the-dicer-enzyme-2f022f26c930">9 Things You Should Know About the Dicer Enzyme</a> was originally published in <a href="https://medium.com/the-biochemists">The Biochemists</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[16 Things You Should Know About Chronic Obstructive Pulmonary Disease (COPD)]]></title>
            <link>https://medium.com/the-biochemists/16-things-you-should-know-about-chronic-obstructive-pulmonary-disease-copd-da80ef1398ab?source=rss-7c0660a6f984------2</link>
            <guid isPermaLink="false">https://medium.com/p/da80ef1398ab</guid>
            <dc:creator><![CDATA[Alpana and Murari Chaudhuri]]></dc:creator>
            <pubDate>Sun, 27 Nov 2016 23:30:11 GMT</pubDate>
            <atom:updated>2017-12-28T22:42:03.233Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="copd" src="https://cdn-images-1.medium.com/max/475/0*AFW5bImTRzv5IDE-.jpeg" /><figcaption>Normal lungs versus lungs with COPD.</figcaption></figure><h4><strong>Overview</strong></h4><p>Chronic obstructive pulmonary disease (COPD) is a family of progressive lung diseases including asthma, chronic bronchitis, and bronchiectasis. These diseases cause slow progressive obstruction of airflow into and out of the lung.</p><ol><li>Major symptoms of COPD include increased breathlessness and frequent coughing, together with wheezing and tightness. About 24 million people in the US are affected by COPD.</li><li>There are four stages of COPD: mild COPD (stage I), moderate (II), severe (III), and very severe COPD or end stage COPD (IV). People with stage IV COPD can still function relatively well if they take excellent care of themselves, eat a healthy diet, and take medication for the disease.</li><li>It has been found in bronchial biopsies that a cascade of events occurs during progression from mild to severe COPD. In patients with mild COPD, T-lymphocytes and macrophages are the prevalent inflammatory cells, while total and activated neutrophils predominate in severe COPD. The molecular mechanism causing this change needs to be extensively studied.</li><li>90% of COPD patients are smokers, although not all smokers get COPD. COPD may also develop in people who have long-term contact with harmful pollutants, chemicals, dust, and fumes in the workplace. Long-term contact with second-hand smoke can also cause COPD, as can certain infectious diseases which cause damage to lung tissue.</li><li>Genetic factors contributing to the deficiency of a protein known as alpha-1 antitrypsin may cause COPD. Without the alpha-1 antitrypsin protein, white blood cells begin to attack the lung and lung deterioration occurs. However, not all people with an alpha-1 antitrypsin deficiency have COPD, so further scientific investigation is needed to understand the link between the two.</li><li>People with COPD are at increased risk of developing heart disease, lung cancer, and a variety of other conditions.</li><li>Epidermal growth factor (EGF) and fibroblast growth factor (FGF) are two growth factors involved in pulmonary tissue remodeling; both of these are expressed abnormally in patients with COPD. EGF is expressed at a higher rate in the airway epithelium of COPD patients, while FGF expression is increased in vascular and epithelial compartments in the lungs of COPD patients. Higher vascular EGF expression also leads to increased angiogenesis and tissue remodeling.</li><li>The TGF-B1 protein, a growth factor protein, also has a role in the pathogenesis of COPD. TGF-B1 protein and mRNA expression is higher in lung tissue and airway epithelial cells in patients with mild to moderate COPD.</li><li>Protein and mRNA levels of different cell-signaling proteins, known as cytokines and chemokines, are also altered in COPD patients.</li><li>Medical treatment for COPD includes various bronchodialators, steroids, and enzyme inhibitors, as well as medications to help patients stop smoking.</li><li>At present, two new medications are available for patients with moderate to severe COPD. One is an antibiotic, known as azithromycin, that also has anti-inflammatory effects to decrease COPD exacerbation and improve quality of life. The second medication is roflumilas, which also reduce COPD exacerbation.</li><li>Based on the cytokine and growth factor actions in human airways, specific anti-inflammatory therapies are being developed for COPD. Antagonists of a cytokine known as TNF-alpha reduce inflammation and tissue destruction by down-regulation of matrix metalloproteinases (MMP). There are multiple clinical trials for COPD with different TNF-alpha and chemokine antagonists are worthwhile.</li><li>Recently, scientists have begun exploring stem cell therapy for COPD. Stem cells can promote healing in lungs affected by COPD; the procedure is minimally invasive and the cells will not be rejected by the body.</li><li>New research shows that a specific type of white blood cell can be manipulated to ease the body’s immune response to COPD. Nanoparticles can be used to deliver drugs in a highly-targeted fashion to activate immune cells and could be designed to treat a broad range of inflammatory diseases, including COPD.</li><li>Though research progress in this field is slow there encouraging indication for future research.</li><li>New experimental approaches and techniques that are aptly suited to COPD research have been developed, but there is still a long way to go to find a permanent cure for COPD.</li></ol><h4><strong>Further Reading</strong></h4><p>William I. de Boer, Vijay K.T. Alagappan, and Hari S. Sharma (2007). Molecular mechanisms in chronic obstructive pulmonary disease: potential targets for therapy. Cell Biochem Biophysics. 47, 131–147.</p><p>Zhenjia Wang, Jing Li, Jachyung Cho, and Asar B. Malik (2014). Prevention of vascular inflammation by nanoparticle targeting of adherent neutrophils. Nature Nanotechnology 9, 204–210.</p><p>J.C. Hogg, et al (2004). The nature of small airway obstruction in chronic obstructive pulmonary disease. New Eng J. Med., 350 (10), 1005–1012.</p><p>P.J.Barnes, S.D. Shapiro, and R.A. Pawels (2003). Chronic obstructive pulmonary disease: Molecular and Cellular mechanisms. European Resp.J., 22 (4), 672–688.</p><h4><strong>Picture Credit</strong></h4><p>National Heart, Lung, and Blood Institute. <a href="https://www.nhlbi.nih.gov/health/health-topics/topics/copd.">https://www.nhlbi.nih.gov/health/health-topics/topics/copd.</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=da80ef1398ab" width="1" height="1" alt=""><hr><p><a href="https://medium.com/the-biochemists/16-things-you-should-know-about-chronic-obstructive-pulmonary-disease-copd-da80ef1398ab">16 Things You Should Know About Chronic Obstructive Pulmonary Disease (COPD)</a> was originally published in <a href="https://medium.com/the-biochemists">The Biochemists</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[13 Things You Should Know About Zika Virus]]></title>
            <link>https://medium.com/the-biochemists/13-things-you-should-know-about-zika-virus-cd2d0b1492a9?source=rss-7c0660a6f984------2</link>
            <guid isPermaLink="false">https://medium.com/p/cd2d0b1492a9</guid>
            <dc:creator><![CDATA[Alpana and Murari Chaudhuri]]></dc:creator>
            <pubDate>Sun, 26 Jun 2016 20:56:34 GMT</pubDate>
            <atom:updated>2017-12-28T22:42:04.400Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="rossmann-zika" src="https://cdn-images-1.medium.com/max/1024/0*Q8l1RVjkff_THZ4v.jpg" /><figcaption>The Zika virus has unique surface carbohydrates, shown in red.</figcaption></figure><h4><strong>Overview</strong></h4><ol><li>The Zika virus was first isolated in 1947 from the Zika forest of Uganda; this is where the virus gets its name.</li><li>Zika is related to Dengue, yellow fever, Japanese encephalitis, and the West Nile virus.</li><li>The virus has caused epidemics in several regions around the world in recent years. Initial outbreaks have been in Africa and Asia, but a recent outbreak of the Zika virus was confirmed in 2015 in Brazil. Currently, about one million Brazilians have been infected, according to the WHO.</li><li>It is thought that the virus came to Brazil during the Va’a World Sprint Championship canoe race, which brought together infected international travelers in close promixity. The disease was able to spread rapidly since both people and mosquitoes had no immunity to the virus, which was new to the region.</li><li>The Zika virus has undergone significant genetic changes since its discovery in Uganda. Researchers believe that some of these mutations are responsible for the birth defects associated with the virus, as the mutated virus replicates more efficiently and invades new tissue. These changes at least partially explain the exponential spread of the virus in the Americas.</li><li>Zika virus is primarily transmitted to humans from Aedes aegypti and Aedes albopictus, two species mosquitoes.</li><li>There is no widely available test for Zika because it may cross-react with antibody tests for dengue and yellow fever. A diagnosis of Zika infection can only be confirmed by laboratory testing for the presence of Zika virus RNA in the blood or other bodily fluids, such as urine or saliva.</li><li>The symptoms of Zika virus are mild and include a flu-like illness with fever, rash, joint pain, and red eyes. However, recent findings have shown that pregnant women infected with this virus give birth to babies with an unusually small head and an underdeveloped brain- a condition known as microcephaly. The recent outbreak in Brazil is alarming because it is associated with a significant increase in microcephaly in newborns.</li><li>Researchers are also studying a possible link between an increase of Guillain-Barre Syndrome (GBS) and infection with the Zika virus. GBS is a condition in which a person’s immune system attacks part of the peripheral nervous system. In severe cases, this syndrome leads to paralysis.</li><li>A mother already infected with the virus can pass the virus to her newborn near the time of delivery. The virus can cross the placental barrier and attack fetal nerve cells, including some cells that develop into the brain. There are also multiple reports of transmission of the virus through blood transfusion.</li><li>The Zika virus is a positive single-strand RNA virus and is a member of the Flavivirus genus in the family Flaviviridae. Its genome size is 10 kb long and encodes three structural proteins — the capsid, pre-membrane/membrane, and envelope. By sequence homology, Zika is similar to Dengue and West Nile. One notable difference of Zika virus from Dengue and other viruses is in the key surface protein, E-glycoprotein.</li><li>The variation in the E-glycoprotein of Zika virus could explain the ability of the virus to attack nerve cells, as well as the association of Zika virus infection with birth defects and the autoimmune disease GBS.</li><li>The structure of E-glycoprotein in Zika virus could inform vaccine development, as the it is a key target of immune responses. The information may also be useful for designing treatments, such as antiviral drugs or antibodies that interfere with E-glycoprotein function. Furthermore, extensive analysis of the structural difference of E-glycoprotein in the Zika virus and in Dengue may be helpful to develop a diagnostic test that will differentiate the two viruses.</li></ol><h4><strong>Further Reading</strong></h4><p>Robert P. Kruger (2016) Zika virus on the move. Cell. 164(4), 585–587.</p><p>Wang and Valderramos et al (2016) From mosquito to humans: Genetic evolution of Zika virus. Cell Host Microbes doi; 10: 1016/ j. chom. 2016.04.006.</p><p>Jernej Malkar et al. (2016) Zika virus associated with Microcephaly. The New England J. of Medicine Page 1–8 doi. 10:1056/NEJMoa1600 651.</p><p>Sirohi, D; Chen, Z; Sun, L; Klose, T; Pierson, T.C; Rossmann, M.G; Kuhn,R.J. (2016) The 3.8 A resolution cryo-EM structure of Zika virus. Science. oid 10:1126/Science aaf5316.</p><h4><strong>Picture Credit</strong></h4><p>Purdue University. <br>http://www.purdue.edu/newsroom/releases/2016/Q1/researchers-reveal-zika-virus-structure,-a-critical-advance-in-the-development-of-treatments.html</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=cd2d0b1492a9" width="1" height="1" alt=""><hr><p><a href="https://medium.com/the-biochemists/13-things-you-should-know-about-zika-virus-cd2d0b1492a9">13 Things You Should Know About Zika Virus</a> was originally published in <a href="https://medium.com/the-biochemists">The Biochemists</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
    </channel>
</rss>